LITTLETON, CO -- (MARKET WIRE) -- 02/12/04 -- Zynex Medical
Holdings, Inc. (OTC BB: ZYNX) announced today it has completed its
acquisition of Zynex Medical, Inc. ("Zynex") Since 1996, Zynex has
been a leading provider of relief for patients with functional
disability through the creation, distribution and marketing of the
highest quality electrotherapy products available today.

Zynex continually strives to uphold its mission to improve the
quality of life of patients suffering from debilitating pain or
illness by providing the highest technology and service standards in
the electrotherapy industry. Utilizing various methods of
non-invasive muscle stimulation and state-of-the-art electromyography
technology, Interferential Current (IFC) and Transcutaneous
Electrical Nerve Stimulation (TENS), Zynex offers patients a new
lease on life through increased mobility and independence.

Founded on the principle that a commitment to high-quality patient
life through non-invasive rehabilitation products can be a profitable
as well as rewarding endeavor, Zynex has long dedicated itself to
satisfying both its investors and the patients they serve.

Details of the acquisition can be found in the Company's 8-K filing
of February 4, 2004.

Thomas Sandgaard, CEO of Zynex Medical, Inc. commented on the
acquisition by stating, "We are excited to close this acquisition and
plan to bring significant value to the shareholders of Zynex Medical
Holdings, Inc."

"Safe Harbor" Statement: Certain statements in this release are
"forward-looking" statements. Such statements are subject to
numerous risks and uncertainties. Actual results may vary
significantly from the results expressed or implied in such
statements. Factors that could cause actual results to materially
differ from forward-looking statements include, but are not limited
to, the Company's ability to meet the terms and conditions required
to obtain its project financing, risks and delays associated with
product development, risk of market acceptance of new products, risk
of technology or product obsolescence, competitive risks, reliance on
development partners and the need for additional capital.

Contact Information:

Zynex Medical Holdings, Inc.
Thomas Sandgaard
CEO
(303) 707-0203 www.zynexmed.com